Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 35,371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Interventions: ALLO-316, ALLO-647, Fludarabine, Cyclophosphamide; Genetic · Biological · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Digestive System Disease
Interventions: Low-dose PvP001, Medium-dose PvP001, High-dose PvP001, Placebo; Drug
Lead sponsor: Danielle Kim Turgeon; Other
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Sclerosis
Interventions: Resilience-Based Program for Support Partners of PwMS; Behavioral
Lead sponsor: Healios Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Flemington, New Jersey

Conditions: Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions: Siemens 3T PRISMA MR Scanner, PET/CT Scanner, Suvorexant, Placebo; Device · Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postoperative Wound Complications
Interventions: Negative pressure wound therapy; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 10 Years to 64 Years · Female only
Enrollment: 441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer Survivorship
Interventions: Time-restricted eating; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Prevention of Zika Infection, Zika-Specific Immune Response
Interventions: VRC-ZKADNA090-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Participants
Interventions: TAK-954, Itraconazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: PTSD
Interventions: Psychedelic; Drug
Lead sponsor: Scottsdale Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Parkinson's Disease
Interventions: HNC364; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Lymphoma, Non-Hodgkin
Interventions: DZD8586, Placebo; Drug
Lead sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Advanced Malignancies
Interventions: INCAGN01949, Nivolumab, Ipilimumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more

Conditions: Peyronie's Disease
Interventions: AA4500; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Burbank, California

Conditions: Healthy Volunteers
Interventions: TAK-915; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer
Interventions: Insertion of Pressure Equalization (PE) Tubes, Sodium Thiosulfate (STS), Saline (Placebo), Cisplatin; Procedure · Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Renal Insufficiency
Interventions: Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Chronic Hypertension
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Overland Park, Kansas • Willingboro, New Jersey

Conditions: Iron Overload, Excessive Body Iron Burden
Interventions: R2*-UTE, R2*-GRE, Liver biopsy; Device · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions: Carboplatin, Paclitaxel, Lapatinib, Cisplatin, Ipsilateral Radiation, Bilateral Radiation, Transoral Surgery; Drug · Radiation · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: High Risk for Falling
Interventions: PUP™ sock; Device
Lead sponsor: Tammy Moore; Other
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions: Stopping Heart Failure Medication(s); Other
Lead sponsor: Dinesh Thavendiranathan; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Trauma, Opioid Use, Spine Fusion
Interventions: Oxycodone, Ketorolac, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

Gastric Gluten-Degradation Activity of PvP001

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Negative Pressure Wound Therapy in Cesarean Section

Time-restricted Eating in Cancer Survivorship: A Single-arm Feasibility Pilot Study

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Massive Iron Deposit Assessment

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Testing the Effectiveness of a Falls Prevention System

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

The STOP-MED CTRCD Trial

Relieving Acute Pain (RAP) Study: A Pilot Study